Zai Lab Ltd (NASDAQ:ZLAB) has been given a consensus recommendation of “Hold” by the six brokerages that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $37.50.
ZLAB has been the subject of several recent research reports. BidaskClub cut Zai Lab from a “hold” rating to a “sell” rating in a report on Friday, September 7th. Zacks Investment Research cut Zai Lab from a “buy” rating to a “hold” rating in a report on Thursday, September 6th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $43.00 price target on shares of Zai Lab in a report on Thursday, June 28th.
Shares of NASDAQ:ZLAB traded down $0.97 during midday trading on Monday, hitting $18.25. The company had a trading volume of 195,914 shares, compared to its average volume of 127,039. Zai Lab has a twelve month low of $17.17 and a twelve month high of $35.74. The stock has a market cap of $1.13 billion and a PE ratio of -7.87.
About Zai Lab
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.
Read More: Fiduciary
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.